Lund, Sweden – 24 April 2014 – BioInvent International AB (OMXS: BINV)

BioInvent’s Annual General Meeting on 24 April resolved to authorize the Board of Directors to issue new shares. All Board members were re-elected by the Annual General Meeting.

The AGM voted in favour of adopting the income statements and balance sheets for the Group and the parent company, and decided that the profits at the disposal of SEK 14,541,267 should be carried forward.

The AGM discharged the Board members and each CEO from liability, reelected the ordinary board members Björn O. Nilsson, Lars Backsell, Dharminder Chahal, Lars Ingelmark, Jonas Jendi and Elisabeth Lindner. Björn O. Nilsson was re-elected Chairman of the Board.

Further, the AGM resolved that the Board’s fees shall remain unchanged at SEK 400,000 for the Chairman of the Board and SEK 160,000 for each of the other members of the Board not employed by the Company. In addition hereto, it was decided that the fee for the Chairman of the Audit Committee shall amount SEK 50,000, that the fee for each of the other members in the Audit Committee shall amount to SEK 40,000 and that the fee for each of the members in the Remuneration Committee, if any, shall amount to SEK 20,000. Fee for Committee work shall however not be paid to the Chairman of the Board.

The AGM also resolved in accordance with the Board’s proposal on guidelines for remuneration of executive management.

Last, the AGM authorized the Board of Directors to resolve on the issue of new shares, with or without a deviation from the shareholders’ preferential right, of a maximum number of shares which corresponds to 15 per cent of the registered share capital, for the purpose of increasing the company’s financial flexibility, to add new company owners of strategic importance and/or the acquisition of other companies or businesses.

                                                                 -- END --

To the editors:

About BioInvent
BioInvent International AB is a research-based pharmaceutical company focused on discovery and development of innovative antibody-based drugs against cancer. The Company's pipeline currently includes three product candidates for the treatment of cancer.

The company has unique expertise in antibody drug development from initial concept to late clinical phase. The screening tool F.I.R.S.T.TM and the antibody library n-CoDeR® are two patented tools that enable identification of relevant human antibodies and disease targets during the discovery phase. The scope and strength of this platform is also used to develop antibody-based drugs in collaboration with partners who finance the development of the new drug, and provide BioInvent the right to milestone payments and royalties on sales. These partners include Bayer Pharma, Daiichi Sankyo, Les Laboratoires Servier and Mitsubishi Tanabe Pharma.
www.bioinvent.com.

For further information, please contact:

Michael Oredsson                                                 Björn O. Nilsson
President and CEO                                               Chairman of the board
+46 (0)46 286 85 67                                             +46 (0)702 18 15 00
+46 (0)707 16 89 30
[email protected]

BioInvent International AB (publ)
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
[email protected]
www.bioinvent.com

Legal disclaimer
The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same was as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

Information disclosed in this press release is provided herein pursuant to the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 0.45 p.m. CET, on 24 April, 2014.